Adverse outcome pathways (AOPs) are a recent toxicological construct that connects, in a
formalized, transparent and quality-controlled way, mechanistic information to apical …

A plethora of human hepatocyte-based in vitro systems for toxicity testing has been
developed over the past few years. These systems are either directly derived from liver …

Background & Aims Cholemic nephropathy (CN) is a severe complication of cholestatic liver
diseases for which there is no specific treatment. We revisited its pathophysiology with the …

Drug-induced liver injury (DILI) cannot be accurately predicted by animal models. In
addition, currently available in vitro methods do not allow for the estimation of hepatotoxic …

Mouse models of non-alcoholic fatty liver disease (NAFLD) are required to define
therapeutic targets, but detailed time-resolved studies to establish a sequence of events are …

Bile duct ligation (BDL) is an experimental procedure that mimics obstructive cholestatic
disease. One of the early consequences of BDL in rodents is the appearance of so‐called …

The mycotoxin ochratoxin A (OTA) is a contaminant in food that causes nephrotoxicity and to
a minor degree hepatotoxicity. Recently, we observed that OTA induces liver damage …

Little is known about how liver fibrosis influences lobular zonation. To address this question,
we used three mouse models of liver fibrosis, repeated CCl4 administration for 2, 6 and 12 …

Epigenetic modifications (eg DNA methylation) in NAFLD and their contribution to disease
progression and extrahepatic complications are poorly explored. Here, we use an integrated …

Acetaminophen (APAP) is one of the most intensively studied compounds that causes
hepatotoxicity in the pericentral region of the liver lobules. However, spatio-temporal …